Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

NCT04722640 · clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
240
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Istituto Clinico Humanitas